DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Novel PCSK9 Inhibitors and Other Novel Antidyslipidemic ( For reducing cardiovascular risk) | Physician & Payer Forum | US | 2015
A Survey of Noninterventional Cardiologists, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors The primary goal of therapy for individuals with dyslipidemia is to…
Osteoarthritic Pain – As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? | Decision Base | US/EU5 | 2015
As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? Osteoarthritis (OA) is a tremendously prevalent condition…
The Impact of Biosimilars in NHL, Breast Cancer, and Colorectal Cancer | Physician & Payer Forum | Brazil and Mexico | 2015
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…
Biosimilars Advisory Service : Global Biosimilars Markets – Regulations, Pipelines, and Major Players | G7 | 2015
Latest update: Global Biosimilars Pipeline updated on 31 July 2015 The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 75%…
